Trial · NCT07905612
Singing Therapy for Rehabilitating Facial Mimicry in Parkinson's Disease: A Randomised Controlled Trial
NCT07905612, Not applicable, Completed, Toronto Metropolitan University
3 sourcestrials-2026-11-12-0.5.0
Download JSON
Cite this record
ConductScience Library. Singing Therapy for Rehabilitating Facial Mimicry in Parkinson's Disease: A Randomised Controlled Trial. Trials, record NCT07905612. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07905612
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Singing Therapy for Rehabilitating Facial Mimicry in Parkinson's Disease: A Randomised Controlled Trial
- NCT number
- NCT07905612
- Status
- Completed
- Phases
- Not applicable
- Enrollment
- 48 participants, actual
- Lead sponsor
- Toronto Metropolitan University
- Conditions
- PARKINSON DISEASE (Disorder)
- Interventions
- Singing Imitation Therapy, Singing Observation Therapy
- First posted
- 2026-10-29
- Last updated
- 2026-10-29
Source ClinicalTrials.gov
Registered outcomes44
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change in Standardized Facial Muscle Activity From Week 1 to Week 13 | Week 1 and Week 13 (end of treatment). | Change in standardized facial muscle activity from Week 1 to Week 13. Surface electromyography is recorded from the zygomaticus major, corrugator supercilii, and medial frontalis during emotional speech and song observation. Mean activity 1-4 seconds after stimulus onset is expressed as percentage change from a 2-second prestimulus baseline, then standardized within participant and muscle, then within participant across muscles. Both recordings at each visit are included. Activity is retained by muscle and stimulus emotion. Analyses assess overall responsiveness across emotional trials, excluding neutral/calm, and emotion-congruent responses: happy versus neutral/calm for zygomaticus; negative emotions (sad, angry, fearful, disgust) versus neutral/calm for corrugator; and surprise versus neutral/calm for frontalis. Values are unitless with no fixed limits; positive changes indicate increased activity. |
| Primary | Change in Standardized Facial Muscle Activity From Week 1 to Two Months After Treatment | Week 1 and two months after completion of the 13-week intervention. | Change in standardized facial muscle activity from Week 1 to two months after treatment completion. Surface electromyography is recorded from the zygomaticus major, corrugator supercilii, and medial frontalis during emotional speech and song observation. Mean activity 1-4 seconds after stimulus onset is expressed as percentage change from a 2-second prestimulus baseline, then standardized within participant and muscle, then within participant across muscles. Both recordings at each visit are included. Activity is retained by muscle and stimulus emotion. Analyses assess overall responsiveness across emotional trials, excluding neutral/calm, and emotion-congruent responses: happy versus neutral/calm for zygomaticus; negative emotions (sad, angry, fearful, disgust) versus neutral/calm for corrugator; and surprise versus neutral/calm for frontalis. Values are unitless with no fixed limits; positive changes indicate increased activity. |
| Primary | Change in Modified MDS-UPDRS Part III Motor Examination Total Score From Week 1 to Week 13 | Week 1 and Week 13 (end of treatment). | Change from Week 1 to Week 13, calculated as the Week 13 value minus the Week 1 value. Motor impairment is assessed using Part III of the Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS). The postural-stability item was not administered. The modified total comprises the remaining 32 ratings, each scored 0-4; eligible partially completed assessments are prorated to the 32-rating scale. Total scores range from 0 to 128, with higher scores indicating greater impairment. Change scores range from -128 to 128. Negative changes indicate reduced motor impairment. |
| Primary | Change in Modified MDS-UPDRS Part III Motor Examination Total Score From Week 1 to Two Months After Treatment | Week 1 and two months after completion of the 13-week intervention. | Change from Week 1 to two months after treatment completion, calculated as the follow-up value minus the Week 1 value. Motor impairment is assessed using Part III of the Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS). The postural-stability item was not administered. The modified total comprises the remaining 32 ratings, each scored 0-4; eligible partially completed assessments are prorated to the 32-rating scale. Total scores range from 0 to 128, with higher scores indicating greater impairment. Change scores range from -128 to 128. Negative changes indicate reduced motor impairment. |
| Primary | Change in MDS-UPDRS Part III Facial Expression Score From Week 1 to Week 13 | Week 1 and Week 13 (end of treatment). | Change from Week 1 to Week 13, calculated as the Week 13 value minus the Week 1 value. Facial expression is assessed using item 3.2 of the Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS), Part III. This clinician-rated item assesses reduced facial expression, including blinking, spontaneous smiling, and lower-face movement. Scores range from 0 to 4, with higher scores indicating greater impairment. Change scores range from -4 to 4. Negative changes indicate reduced facial-expression impairment. |
| Primary | Change in MDS-UPDRS Part III Facial Expression Score From Week 1 to Two Months After Treatment | Week 1 and two months after completion of the 13-week intervention. | Change from Week 1 to two months after treatment completion, calculated as the follow-up value minus the Week 1 value. Facial expression is assessed using item 3.2 of the Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS), Part III. This clinician-rated item assesses reduced facial expression, including blinking, spontaneous smiling, and lower-face movement. Scores range from 0 to 4, with higher scores indicating greater impairment. Change scores range from -4 to 4. Negative changes indicate reduced facial-expression impairment. |
| Primary | Change in MDS-UPDRS Part III Speech Score From Week 1 to Week 13 | Week 1 and Week 13 (end of treatment). | Change from Week 1 to Week 13, calculated as the Week 13 value minus the Week 1 value. Speech is assessed using item 3.1 of the Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS), Part III. This clinician-rated item assesses speech volume, modulation, and clarity. Scores range from 0 to 4, with higher scores indicating greater speech impairment. Change scores range from -4 to 4. Negative changes indicate reduced speech impairment. |
| Primary | Change in MDS-UPDRS Part III Speech Score From Week 1 to Two Months After Treatment | Week 1 and two months after completion of the 13-week intervention. | Change from Week 1 to two months after treatment completion, calculated as the follow-up value minus the Week 1 value. Speech is assessed using item 3.1 of the Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS), Part III. This clinician-rated item assesses speech volume, modulation, and clarity. Scores range from 0 to 4, with higher scores indicating greater speech impairment. Change scores range from -4 to 4. Negative changes indicate reduced speech impairment. |
| Secondary | Emotion-Recognition Accuracy at Week 13 | Week 13 (end of treatment). | Emotion recognition is assessed during the audiovisual speech and song task. After each video, participants select the emotion portrayed. Neutral and calm are combined into a single category for both target emotions and participant responses before scoring. Each valid response is scored 1 if it matches the target category after this grouping and 0 otherwise. Accuracy is expressed as the percentage of correct responses, from 0% to 100%, with higher values indicating more accurate recognition. Responses from both recordings at the assessment visit are included. |
| Secondary | Emotion-Recognition Accuracy at Two Months After Treatment | Two months after completion of the 13-week intervention. | Emotion recognition is assessed during the audiovisual speech and song task. After each video, participants select the emotion portrayed. Neutral and calm are combined into a single category for both target emotions and participant responses before scoring. Each valid response is scored 1 if it matches the target category after this grouping and 0 otherwise. Accuracy is expressed as the percentage of correct responses, from 0% to 100%, with higher values indicating more accurate recognition. Responses from both recordings at the assessment visit are included. |
1 to 10 of 44Source ClinicalTrials.gov
See all 44 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 27375505 | RESULT |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07905612
GET https://conductscience.org/api/trials/v1/NCT07905612/registered?page=2